Sanofi SA

Narisara Nami | Moment | Getty ImagesA panel of independent advisors to the Food and Drug Administration unanimously recommended Thursday that the antibody nirsevimab be approved for use to protect infants from respiratory syncytial virus, the leading cause of hospitalization among newborns.If the FDA approves nirsevimab, the antibody would become the first medical intervention available in the U.S. that can protect all infants from RSV. The FDA, which is not obligated to follow the recommendation of its advisory panel,…

Eli Lilly CEO Dave Ricks on Wednesday promised not to raise prices on the company's insulin products again — the only executive to do so before a Senate Health Committee hearing on making the life-saving diabetes drug more affordable.Sen. Bernie Sanders, the committee's chair, asked Ricks and the CEOs of Novo Nordisk and Sanofi to commit to "never increase the price of any insulin drug again." The three companies control over 90% of the global insulin market. Ricks was the only executive who outright agreed to Sanders'…

In this photo illustration, an insulin pen manufactured by the Novo Nordisk company is displayed on March 14, 2023 in Miami, Florida.Joe Raedle | Getty Images News | Getty ImagesThe top executives of the three drug companies that control 90% of the global insulin market will testify May 10 before the Senate Health Committee on lowering prices of their diabetes drugs, panel Chairman Sen. Bernie Sanders said Friday.Those companies — Eli Lilly, Novo Nordisk and Sanofi — had announced in March that they will slash prices of…

Scott Olson | Getty ImagesCheck out the companies making the biggest moves midday:Target — Shares of the retailer slid more than 2% after its earnings missed Wall Street expectations by a wide margin. The company said its quarterly profit fell almost 90% from a year ago. However, Target reiterated its full-year forecast and said it is now positioned for a rebound.Bed Bath & Beyond — Shares of the meme stock jumped about 22% on Wednesday, continuing a torrid August rally for the challenged retailer. The stock has seen…

Shares of GlaxoSmithKline, Sanofi and Haleon all sold off sharply this week, shedding tens of billions in market value, amid investor fear over potential U.S. litigation charges focused on popular heartburn drug Zantac. This has been a known issue bumbling in the background for years but investor concern exploded this week in the lead-up to the first scheduled legal proceeding on Aug 22.What is Zantac?Zantac is the brand name for a drug called ranitidine, a medicine used to relieve heartburn. It was originally invented…

Check out the companies making headlines before the bell:Yamana Gold (AUY) – The Canadian gold producer agreed to be acquired by Gold Fields (GFI) in an all-stock deal valued at $6.7 billion. Yamana Gold shareholders will receive 0.6 Gold Field shares for each share they now hold. Yamana surged 14.9% in the premarket while Gold Fields tumbled 11.8%.Credit Suisse (CS) – Credit Suisse denied a Reuters report that it is mulling various options to raise capital after a series of losses. Two people with knowledge of the matter…

Nio began deliveries of its new ET7, an upscale electric sedan, on Monday, March 28, 2022.NioCheck out the companies making headlines in midday trading.Marathon Oil, Diamondback Energy — Energy stocks rose along with oil prices after an agreement from European Union leaders to ban most crude imports from Russia stoked inflation fears. Shares of Marathon Oil jumped more than 4%, and shares of Diamondback Energy gained 1.9%.Alibaba, JD, Baidu — A slew of Chinese stocks listed in the U.S. rallied after the country's Covid-19…